[EN] PLASMA KALLIKREIN INHIBITORS<br/>[FR] INHIBITEURS DE LA KALLICRÉINE PLASMATIQUE
申请人:MERCK SHARP & DOHME
公开号:WO2021257353A1
公开(公告)日:2021-12-23
The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.
本发明提供了一种式(I)的化合物,以及包括一种或多种所述化合物的药物组合物,并且使用所述化合物治疗或预防可能受益于抑制血浆激肽酶的一种或多种疾病状态的方法,包括遗传性血管性水肿、葡萄膜炎、后部葡萄膜炎、湿性老年性黄斑水肿、糖尿病性黄斑水肿、糖尿病视网膜病变和视网膜静脉阻塞。这些化合物是血浆激肽酶的选择性抑制剂。